Provincial Funding Boosts Local Health Tech Innovation
A Newfoundland and Labrador health tech company has secured significant provincial funding to bring its innovative congestive heart failure monitoring solution to market. JVPLabs will receive an investment of over $500,000 to support the research and development of its JVPClinic medical device.
The JVPClinic technology uses non-invasive imaging to measure jugular venous pressure, providing crucial data on heart function. By capturing subtle motion signatures from blood vessels beneath the skin, the device enables healthcare providers to adjust treatments before patients develop severe symptoms. This early intervention aims to reduce hospital congestion and allow patients to manage their condition comfortably at home.
Congestive heart failure affects approximately 750,000 Canadians, with 100,000 new diagnoses annually. The global prevalence is even more staggering, with over 25 million patients worldwide. The provincial government’s funding will support device development, fabrication, R&D, third-party testing, and AI enhancement for the JVPClinic technology.
JVPLabs has a proven track record of successful R&D projects with local health authorities. Previous collaborations have led to the development of earlier JVPClinic prototypes, which have been tested in clinical trials at Eastern Health in partnership with the Health Innovation Team.
